BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27037031)

  • 21. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
    Kleist B; Meurer T; Poetsch M
    Tumour Biol; 2017 Mar; 39(3):1010428317692246. PubMed ID: 28345467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
    Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
    Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
    Li L; Ni BB; Zhong QH; Liu YH; Zhang MH; Zhang KP; Chen DC; Wang L
    Future Oncol; 2017 Jul; 13(17):1473-1492. PubMed ID: 28685592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases.
    Barresi V; Bonetti LR; Bettelli S
    Pathology; 2015 Oct; 47(6):551-6. PubMed ID: 26352110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
    Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
    Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.
    Lennerz JK; van der Sloot KWJ; Le LP; Batten JM; Han JY; Fan KC; Siegel CA; Srivastava A; Park DY; Chen JH; Sands BE; Korzenik JR; Odze RD; Dias-Santagata D; Borger DR; Khalili H; Iafrate AJ; Lauwers GY
    Int J Colorectal Dis; 2016 May; 31(5):973-982. PubMed ID: 27026089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colorectal cancer metastatic to the brain: analysis of prognostic factors and impact of KRAS mutations on presentation and outcome.
    Nieder C; Hintz M; Grosu AL
    Clin Transl Oncol; 2016 Jan; 18(1):88-92. PubMed ID: 26260912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
    Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
    Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.
    Grellety T; Gros A; Pedeutour F; Merlio JP; Duranton-Tanneur V; Italiano A; Soubeyran I
    Virchows Arch; 2016 Oct; 469(4):459-64. PubMed ID: 27401719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
    Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
    Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
    Jeantet M; Tougeron D; Tachon G; Cortes U; Archambaut C; Fromont G; Karayan-Tapon L
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.